4 Houstonians join Texas Business Hall of Fame

Leading texans

Four of the six inductees are from Houston. Photos courtesy

The Texas Business Hall of Fame Foundation has inducted six new Texans to its prestigious ranks — and four run their businesses from the Bayou City.

John Arnold, Ric Campo, Jeffery D. Hildebrand, and Paul W. Hobby — along with Austin-based Whitney Wolfe Herd and Dallas-based Thomas O. Hicks — will be honored at Texas Business Hall of Fame Foundation's 40th Anniversary and Induction Dinner on on November 3.

“The Texas Business Hall of Fame is pleased to announce its six inductees for 2022," says TBHF Chair Amanda Brock in a news release. "Inductees are recognized as trailblazers in business and exemplary leaders who have made significant contributions in their local communities and beyond, through both philanthropic and civic engagement. Although inductees can be nominated by anyone from the general public, they are selected by their peers and determined by a majority vote by Hall of Fame members."

The TBHF honors business leaders across the state by celebrating and telling their stories. The organization also runs the Future Legends Scholar & Veteran Award Program that grants forty $15,000 awards to scholars and veterans who demonstrate entrepreneurship and innovation at 24 universities throughout the Lone Star State. Both the scholars and the six honorees will celebrated this fall.

“The selection process, combined with the organization’s emphasis on both economic and social impact makes this one of the most prestigious business honors in the state,” says TBHF Legend and the 2022 Master of Ceremonies, Richard Fisher.

Here's more information on this year's honorees:

  • Houstonian John Arnold is the founder of Centaurus Capital LP, an energy-focused, family office investment fund. He also created Arnold Ventures, a philanthropic investment firm focused on health care, education, criminal justice, and public finance.
  • Houston-based Camden Property Trust CEO Ric Campo has also sat on the board of directors of several Houston organizations, including Central Houston, Inc., Greater Houston Partnership, Baker Ripley, and The Coalition for the Homeless, and more.
  • Former Dallas Stars and Dallas Rangers, owner Thomas O. Hicks, is the chairman, founder and partner of Hicks Holdings LLC, a family office that owns and manages real estate, corporate assets and investments, including a private equity firm.
  • Jeffery D. Hildebrand, is the executive chairman and founder of Houston-based Hilcorp Energy Company, Harvest Midstream Company, and JDH Capital. He serves on the boards of Central Houston, Inc., the Houston Livestock Show and Rodeo, Houston Police Foundation, Rice University’s Baker Institute for Public Policy, Chairman of The University of Texas Investment Management Company, and the Texas Parks and Wildlife Commission.
  • Houstonian Paul W. Hobby is a founding partner of Genesis Park and GP Capital. He's served as the chairman of the Texas Ethics Commission, the Greater Houston Partnership, the Houston Branch of the Federal Reserve Bank of Dallas ,and the Texas General Services Commission.
  • Austin-based Whitney Wolfe Herd is the founder and CEO of Bumble Inc., the parent company that operates Badoo, Fruitz, and Bumble, three of the world’s fastest growing data apps worldwide. She led Bumble’s IPO in 2021 as the youngest women CEO to ever take a company public.

The awards dinner, presented by Texas Capital Bank, will be hosted in Houston at Hilton Americas on November 3. The dinner is preceded by a private awards luncheon, sponsored by Deloitte, for the Hall of Fame's 40 2022 Scholar & Veteran Award recipients.

Last year's dinner honored six Texans in November 2021, including Houston investment manager Gerald Smith, chairman and CEO of Smith Graham & Co.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings